<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175745</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-29364</org_study_id>
    <secondary_id>NCI-2014-01289</secondary_id>
    <secondary_id>BRN0024</secondary_id>
    <secondary_id>P30CA124435</secondary_id>
    <nct_id>NCT02175745</nct_id>
  </id_info>
  <brief_title>18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas</brief_title>
  <official_title>18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erik Mittra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly
      diagnosed or recurrent gliomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial compares fluorine F-18 fluoro-dihydroxyphenylalanine (18F-fluorodopa or
      18F-FDOPA) positron emission tomography (PET) with standard magnetic resonance imaging (MRI)
      in measuring tumors in patients with glioma that is newly diagnosed or recurrent (has
      returned). 18F-FDOPA is a radioactive drug that binds to tumor cells and is captured in
      images by PET. Computed tomography (CT) and MRI are used with PET to describe information
      regarding the function, location, and size of the tumor. PET/CT or PET/MRI may be more
      accurate than standard MRI in helping doctors find and measure brain tumors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Re-evaluate indication with the referring physicians
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Suspicious Lesions Identified by 18F FDOPA PET</measure>
    <time_frame>Up to 30 minutes after injection of F18 FDOPA</time_frame>
    <description>The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Agreement of 18F FDOPA PET With Pathology</measure>
    <time_frame>Up to 30 minutes post-injection (at time of scan)</time_frame>
    <description>For the subset of lesions where pathology is available (mainly biopsied lesions), the accuracy of 18F FDOPA PET as percent agreement with pathology will be calculated. If the number of biopsy positive lesions is at least 10, an estimate of sensitivity will be calculate; if the number of biopsy negative lesions is at least 10 an estimate of specificity will be calculated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Pineal Gland Astrocytoma</condition>
  <condition>Adult Subependymal Giant Cell Astrocytoma</condition>
  <condition>Childhood High-grade Cerebellar Astrocytoma</condition>
  <condition>Childhood High-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Low-grade Cerebellar Astrocytoma</condition>
  <condition>Childhood Low-grade Cerebral Astrocytoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <condition>Recurrent Childhood Anaplastic Astrocytoma</condition>
  <condition>Recurrent Childhood Anaplastic Oligoastrocytoma</condition>
  <condition>Recurrent Childhood Anaplastic Oligodendroglioma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Diffuse Astrocytoma</condition>
  <condition>Recurrent Childhood Fibrillary Astrocytoma</condition>
  <condition>Recurrent Childhood Gemistocytic Astrocytoma</condition>
  <condition>Recurrent Childhood Giant Cell Glioblastoma</condition>
  <condition>Recurrent Childhood Glioblastoma</condition>
  <condition>Recurrent Childhood Gliomatosis Cerebri</condition>
  <condition>Recurrent Childhood Gliosarcoma</condition>
  <condition>Recurrent Childhood Oligoastrocytoma</condition>
  <condition>Recurrent Childhood Oligodendroglioma</condition>
  <condition>Recurrent Childhood Pilomyxoid Astrocytoma</condition>
  <condition>Recurrent Childhood Protoplasmic Astrocytoma</condition>
  <condition>Recurrent Childhood Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Recurrent Childhood Visual Pathway Glioma</condition>
  <condition>Untreated Childhood Anaplastic Astrocytoma</condition>
  <condition>Untreated Childhood Anaplastic Oligoastrocytoma</condition>
  <condition>Untreated Childhood Anaplastic Oligodendroglioma</condition>
  <condition>Untreated Childhood Brain Stem Glioma</condition>
  <condition>Untreated Childhood Cerebellar Astrocytoma</condition>
  <condition>Untreated Childhood Cerebral Astrocytoma</condition>
  <condition>Untreated Childhood Diffuse Astrocytoma</condition>
  <condition>Untreated Childhood Fibrillary Astrocytoma</condition>
  <condition>Untreated Childhood Gemistocytic Astrocytoma</condition>
  <condition>Untreated Childhood Giant Cell Glioblastoma</condition>
  <condition>Untreated Childhood Glioblastoma</condition>
  <condition>Untreated Childhood Gliomatosis Cerebri</condition>
  <condition>Untreated Childhood Gliosarcoma</condition>
  <condition>Untreated Childhood Oligoastrocytoma</condition>
  <condition>Untreated Childhood Oligodendroglioma</condition>
  <condition>Untreated Childhood Pilomyxoid Astrocytoma</condition>
  <condition>Untreated Childhood Protoplasmic Astrocytoma</condition>
  <condition>Untreated Childhood Subependymal Giant Cell Astrocytoma</condition>
  <condition>Untreated Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Untreated Childhood Visual Pathway Glioma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (FDOPA-PET/CT or PET/MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-fluoro-dihydroxyphenylalanine</intervention_name>
    <description>Administered intravenously (IV)</description>
    <arm_group_label>Diagnostic (FDOPA-PET/CT or PET/MRI)</arm_group_label>
    <other_name>(18)F-FDOPA</other_name>
    <other_name>18F-6-L-fluorodopa</other_name>
    <other_name>18F-DOPA</other_name>
    <other_name>18F-FDOPA</other_name>
    <other_name>Fluorine F-18 fluorodopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission tomography (PET)</intervention_name>
    <description>Component of an 18F-FDOPA PET/CT or PET/MRI scan</description>
    <arm_group_label>Diagnostic (FDOPA-PET/CT or PET/MRI)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed tomography (CT)</intervention_name>
    <description>Component of an 18F-FDOPA PET/CT</description>
    <arm_group_label>Diagnostic (FDOPA-PET/CT or PET/MRI)</arm_group_label>
    <other_name>tomography, computed</other_name>
    <other_name>CT scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
    <description>Component of an 18F-FDOPA PET/MRI</description>
    <arm_group_label>Diagnostic (FDOPA-PET/CT or PET/MRI)</arm_group_label>
    <other_name>MRI scan</other_name>
    <other_name>NMR imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 15 year-old at the time of radiotracer administration

          -  Provides written informed consent

          -  Suspected new diagnosis or suspected recurrence of glioma

          -  Able to remain still for duration of each imaging procedure (about 20 minutes)

        Exclusion Criteria:

          -  Less than 15 year-old at the time of radiotracer administra

          -  Unable to provide informed consent

          -  Inability to lie still for the entire imaging time

          -  Inability to complete the needed investigational and standard-of-care imaging
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Mittra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Hospitals and Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Erik Mittra</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Optic Nerve Glioma</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroxyphenylalanine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (FDOPA-PET/CT or PET/MRI)</title>
          <description>Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (FDOPA-PET/CT or PET/MRI)</title>
          <description>Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Suspicious Lesions Identified by 18F FDOPA PET</title>
        <description>The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.</description>
        <time_frame>Up to 30 minutes after injection of F18 FDOPA</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (FDOPA-PET/CT or PET/MRI)</title>
            <description>Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Suspicious Lesions Identified by 18F FDOPA PET</title>
          <description>The number of suspicious lesions will be identified by uptake of F18 FDOPA radiopharmaceutical using a positron emission tomography (PET) scan. Uptake of F-18 FDOPA is a measure of amino acid uptake and metabolism in tumors. Suspicious lesions will be visually identified by a board certified nuclear medicine physician.</description>
          <units>suspicious lesion(s)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Agreement of 18F FDOPA PET With Pathology</title>
        <description>For the subset of lesions where pathology is available (mainly biopsied lesions), the accuracy of 18F FDOPA PET as percent agreement with pathology will be calculated. If the number of biopsy positive lesions is at least 10, an estimate of sensitivity will be calculate; if the number of biopsy negative lesions is at least 10 an estimate of specificity will be calculated.</description>
        <time_frame>Up to 30 minutes post-injection (at time of scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (FDOPA-PET/CT or PET/MRI)</title>
            <description>Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Agreement of 18F FDOPA PET With Pathology</title>
          <description>For the subset of lesions where pathology is available (mainly biopsied lesions), the accuracy of 18F FDOPA PET as percent agreement with pathology will be calculated. If the number of biopsy positive lesions is at least 10, an estimate of sensitivity will be calculate; if the number of biopsy negative lesions is at least 10 an estimate of specificity will be calculated.</description>
          <units>percentage of agreement (sensitivity)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (FDOPA-PET/CT or PET/MRI)</title>
          <description>Patients receive 18F-FDOPA intravenously (IV) and then undergo PET/CT or PET/MRI 10-30 minutes later. After completion of study, patients are followed up at 24 hours and at 1 week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was underpowered due to low enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Erik Mittra, MD, PhD</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-736-2859</phone>
      <email>emittra@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

